[Lipid lowering, antiinflammatory, and vasoprotective effects of fenofibrate in patients with type 2 diabetes mellitus].
Aim of the study was to assess effect of fenofibrate on lipid blood composition, markers of inflammation and the state of vascular wall in patients with type 2 diabetes mellitus (DB2). We randomized 73 patients with DB2 in 2 groups. Patients of group one (n = 34) in addition to hypoglycemic and lipid lowering therapy with statins received fenofibrate (145 mg/day), patients of control group (n = 38) received standard therapy. We assessed effect of selected therapy on lipids, endothelium dependent vasodilatation (EDVD) in a test with reactive hyperemia of brachial artery, intimaAmedia thickness of common carotid arteries, levels of CAreactive protein (CRP) and uric acid, parameters of stiffness of arterial wall. At the end of the study we found in the fenofibrate group significant lowering of mean levels of total cholesterol, low density lipoprotein cholesterol, CRP, uric acid. We also noted more significant elevation of EDVD, improvement of parameters of arterial wall thickness. The use of fenofibrate in a daily dose 145 mg in patients with DB2 at the background of traditional hypoglycemic, antihypertensive, and lipid lowering therapy corrects effectively lipid disturbances and normalizes function of endothelium and parameters of vascular wall stiffness. This substantially decreases risk of vascular complications of DB2.